China Medical System Holdings (HK:0867) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
China Medical System Holdings has announced the approval of its ruxolitinib phosphate cream for treating non-segmental vitiligo in Hong Kong. This novel treatment offers a new option for the approximately 75,000 vitiligo patients in Hong Kong, providing hope for those struggling with this chronic skin condition. The cream’s approval in various regions reflects its effectiveness and safety, as demonstrated in global clinical studies.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.